Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

cromet-inc.com" target="_new">(http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual result
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , HOERSHOLM, Denmark and SAN DIEGO, Cal...PC3649 Successfully Inhibits miR-122, a microRNA I...y Significantly Reducing Hepatitis C,Virus in the ...th the,Hepatitis C Virus , - SPC3649 Demo...ance and,No Serious Adverse Events in the Treated ...
(Date:12/3/2009)..., SAN DIEGO, Dec. 3 Card...y that its wholly-owned subsidiary, Tissue Repair ... filing with the U.S. Food and Drug Administration...en (TM) product candidate based on positive data ...rix clinical study. Today,s submission with the F...
(Date:12/3/2009)...PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -...unced today that Kathryn E. Falberg has been appoi...icer. Ms. Falberg brings to Jazz Pharmaceuticals ...or experience. As Jazz Pharmaceutical,s CFO, Ms. ...unting, corporate finance, financial planning, inv...
Breaking Medicine Technology:New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Wound Management Technologies 28OTCBB 3A WNDM 29 Reports Revenue Increase of 33 5 25 3B Posts Evidence Based Studies for CellerateRx 3B and Business 6462 1Wound Management Technologies 28OTCBB 3A WNDM 29 Reports Revenue Increase of 33 5 25 3B Posts Evidence Based Studies for CellerateRx 3B and Business 6462 2Wound Management Technologies 28OTCBB 3A WNDM 29 Reports Revenue Increase of 33 5 25 3B Posts Evidence Based Studies for CellerateRx 3B and Business 6462 3Wound Management Technologies 28OTCBB 3A WNDM 29 Reports Revenue Increase of 33 5 25 3B Posts Evidence Based Studies for CellerateRx 3B and Business 6462 4Wound Management Technologies 28OTCBB 3A WNDM 29 Reports Revenue Increase of 33 5 25 3B Posts Evidence Based Studies for CellerateRx 3B and Business 6462 5Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 1Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 2Drug side effects a key factor in reduced quality of life for kidney transplant patients 61930 3Amid the flu epidemic dont forget RSV in young children 61928 1Amid the flu epidemic dont forget RSV in young children 61928 2Amid the flu epidemic dont forget RSV in young children 61928 3
...ery from EAP in 2007, RICHMOND, Va., Jan. 24 Ins...biologics and biopharmaceuticals, today,provided a...(EAP) in Italy,for the treatment of Amyotrophic La...s grown to include 15 physicians and approximately...Additional subjects continue to be,enrolled into t...
...nt Rotavirus, NEW YORK, Jan. 23 Paul Capital Hea...yalty interest in Rotarix(R) from,Cincinnati Child...al,vaccine developed to prevent rotavirus infectio... and dehydration in infants and young children.,Th... has been approved in,over 100 countries including...
Other Medicine Technology:Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis 2Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis 3Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2
(Date:12/3/2009)...wswire/ -- Chiltern International Limited (Chilter...providing clinical development and staffing servic...es the appointment of Dr. Sharon Moore as Execut...ffairs. Dr. Moore is based at Chiltern,s Bristol, ...ian with 15 years of industry experience. Prior to...
(Date:12/3/2009)...3 If you have seen "Super Size Me,...ing look at the other side of the dining table. In...feature documentary, "Supercharge Me! 30 Days Raw"... p.m. at Sever Hall, Harvard Yard. The event is pa.... The film will be followed by a lecture and discu...
(Date:12/3/2009)...ng shapes changed rapidly, researchers say , ...eople think evolution takes hundreds, if not thous...new research shows exactly how: The simple act of ...fect on a population of birds. , Researchers, ...tion of Current Biology , said a single populatio...
(Date:12/3/2009)...swire-USNewswire/ -- The following is being releas... Senate Judiciary Committee Chairman Patrick Leahy...re reform bill that would repeal the health insura...h as price fixing, bid rigging and market allocati...peal, which would subject health insurance compani...
(Date:12/3/2009)...ases created by a single case of H1N1 influenza in...tion, social distancing and the use of antiviral d...rus, suggests an epidemiological modelling study ...ported in CMAJ ( Canadian Medical Association J...ata from laboratory-confirmed cases of H1N1 betwee...
Breaking Medicine News(10 mins):Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:Jenna Norwood to Present Award-Winning Documentary & Lecture at Harvard University 2Health News:Feeding Birds in Winter Could Speed Evolution of Species 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 3Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 4Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 5Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 6Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 7Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 8Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2
...d that at high doses, polyphenols, in green tea or...ing to significant health risks. // The research h...Toronto, results of which can be found in the Free...heart disease and other degenerative disorders ass...
...control patch are twice as likely to develop clots...as found. Recently, another study conducted on sim... risk. With controversial data from both sides, wo...d risk for thromboembolic events or clots in the l...
...linic scientists have unearthed a new virus in hum...und in mice, but not in humans. While it is too ea...virus and // prostate cancer is, the study aims to...ARS virus some three years ago. "This is a virus t...
...entlease is being recalled from the market as stat... particles in some cans. // So this brand would no...tlease powdered infant formula, Mead Johnson Nutri...stification of the company for the recall is publi...
...rnia was slapped with four additional law suits, a...al center had failed miserably. // Orange c...laims filed by the families of patients who died j...nt has to also battle the 50 plus lawsuits that ha...
...rom a poultry in Surat district of Gujarat has tes... resumption of culling operations on chickens, aro... Thankfully, no cases of bird flu among huma...rted in these areas, and 19000 chickens are slated...
Other Medicine News:
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: